Most Read Articles
31 May 2016
Tacrolimus is safe and effective in inducing and maintaining remission in paediatric patients with biologic refractory inflammatory bowel disease (IBD), according to a study presented at the 49th Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition in Athens, Greece.
Rachel Soon, 12 Dec 2018

MIMS Pharmacist presents an overview of superoxide dismutase (SOD) and its role in resisting the effects of oxidative stress and aging.

Rachel Soon, 25 Jul 2018

MIMS Pharmacist presents an overview of Lactobacillus plantarum 299v's physiological role, as well as contemporary research on its pharmacology and effects.

01 Mar 2018
Lifetime prevalence of acute pain leading to the use of analgesics approaches 100% in the general population, and pharmacists are a pivotal first point of contact for patients in their journey to better pain management. Noting the need for pharmacists to be more aware of their evolving role as a community pharmacist, GlaxoSmithKline Consumer Healthcare partnered with MIMS Education to organize a workshop that served as a platform for robust knowledge-sharing. Below are highlights from the workshop.

Dabigatran safety confirmed in real-world study

Pearl Toh
25 Apr 2018

Real-world studies on patients with atrial fibrillation (AF) show that dabigatran is safe with low bleeding and stroke rates when used for long term (over 2 years) or used continuously in patients undergoing cardiovascular (CV) interventions, according to phase II results of the prospective, observational, global registry programme GLORIA-AF* presented at the EHRA 2018 Annual Congress.     

In the first analysis involving 4,873 patients (mean age 70.2 years, 55.6 percent male) with new-onset AF, patients were prescribed dabigatran 150 mg (55 percent), 110 mg (43 percent), or 75 mg (2 percent) for a mean duration of 18.3 months. [EHRA 2018, abstract 1055]

Over 2 years of follow-up, event rates for stroke and major bleeding were low with dabigatran, at 0.65 percent and 0.97 percent, respectively. The findings are consistent with data from other real-world studies, as well as randomized clinical trials such as the RE-LY** EU label analysis which showed a 1.10-percent stroke rate and 3.02-percent major bleeding rate with dabigatran. [Circulation 2015;131:157-164; Thromb Haemost 2014;111:933-942]

Rates of other clinical outcomes such as vascular death (0.85 percent) and life-threatening bleeds (0.46 percent) were also low.

“These prospective data from routine clinical care confirm the sustained safety and effectiveness of dabigatran over 2 years of follow-up … which is reassuring for physicians treating patients with AF,” according to study principal investigator Dr Gregory Lip from University of Birmingham, UK.

According to Lip, the GLORIA-AF study is currently ongoing and the phase III analysis of the programme will provide comparative data on the safety and efficacy of NOACs vs vitamin-K antagonists in the real world.

“Long-term, ‘real-world’ data are important to cardiologists as they help build a bigger picture of how an antithrombotic medication works in daily clinical practice,” he added.

Another analysis of the GLORIA-AF phase II programme included 4,859 patients (mean age 67.2 years, 64.5 percent male) who had been prescribed dabigatran for a mean duration of 18.3 months, of which 332 patients underwent 412 CV interventions with uninterrupted dabigatran. CV interventions included cardioversions (n=299), catheter ablations (n=38), pacemaker implantations (n=25), angiographic procedures (n=26), and angioplasty with or without stenting or catheter-based interventions (n=24). [EHRA 2018, abstract 200]

A mean follow-up of 7.52 weeks showed low rates of stroke/systemic embolism and major bleeds, occurring once each out of 412 interventions (risk, 0.25, 95 percent confidence interval, 0.01–1.36 for both events).

“The prospective analysis supports the favourable safety and effectiveness of dabigatran in clinical practice, complementing randomized trial data,” said Lip, citing the RE-CIRCUIT*** randomized controlled study which showed a 1.6 percent incidence rate of major bleeds during the 8 weeks after ablation. [N Engl J Med 2017;376:1627-1636]

 

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
31 May 2016
Tacrolimus is safe and effective in inducing and maintaining remission in paediatric patients with biologic refractory inflammatory bowel disease (IBD), according to a study presented at the 49th Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition in Athens, Greece.
Rachel Soon, 12 Dec 2018

MIMS Pharmacist presents an overview of superoxide dismutase (SOD) and its role in resisting the effects of oxidative stress and aging.

Rachel Soon, 25 Jul 2018

MIMS Pharmacist presents an overview of Lactobacillus plantarum 299v's physiological role, as well as contemporary research on its pharmacology and effects.

01 Mar 2018
Lifetime prevalence of acute pain leading to the use of analgesics approaches 100% in the general population, and pharmacists are a pivotal first point of contact for patients in their journey to better pain management. Noting the need for pharmacists to be more aware of their evolving role as a community pharmacist, GlaxoSmithKline Consumer Healthcare partnered with MIMS Education to organize a workshop that served as a platform for robust knowledge-sharing. Below are highlights from the workshop.